Abstract B97: Vitamin D and mammographic density in postmenopausal women: A cohort study nested within the NCIC CTG MAP.3 chemoprevention trial

摘要: Background: Vitamin D may be important in the causal pathway to breast cancer (BC) by influencing density, a potential intermediate biomarker for carcinogenesis. However, previous study results are inconsistent, particularly among postmenopausal women. Our objectives were prospectively examine relationship between blood biomarkers of vitamin (serum 25-OH-D) and mammographic density (MD) women at northern latitudes. Potential effect modifications calcium or exemestane therapy on serum 25-OH-D follow-up MD also examined. Methods: The NCIC Clinical Trials Group conducted randomized controlled trial (RCT) comparing (E) with placebo (P) 4560 high risk developing BC (MAP.3) (Goss, NEJM 2011). Using nested observational design, we evaluated cohort participants from across Canada Buffalo, NY. factor information was previously collected; primary exposure outcome data obtained samples mammograms. Serum measured using state-of-the-art LC-MS/MS collected baseline year 1. Values 1 adjusted match month sampling sample these averaged. Baseline ≥ 3 percent centrally assessed, blinded treatment allocation levels, Cumulus software. Linear regression used estimate log transformed controlling confounders age, body mass index, first degree family history calcium. Results: Percent 568 (E=287, P=281) mammogram 21 (91%) Canadian sites participating MAP.3 one US site mean age entry 62 years they followed 3.7 years. geometric mammograms 4.3%. A random 10% (N=102) repeated intra-rater reliability (correlation coefficient = 0.95). Unadjusted collection, concentration 36.5 ng/mL (SD=10.6) based pooled samples. After confounders, not predictive (p=0.25). Statistically significant interactions (above vs. below median value p=0.30) (p=0.99) detected. Preliminary suggest some evidence that low ( Conclusion: In this study, no association levels detected after many well established factors. This funded Breast Cancer Foundation. supported Pfizer. CTG is Society Research Institute. Citation Format: Melanie Walker, Harriet Richardson, Paul Goss, Doris Jabs, Glenville Jones, Martin Kaufmann, Jean Wactawski-Wende, Angela Cheung, Eric Winquist, Silvana Spadafora, Susan Ellard, Amanda Hey, Andrew Cooke, Andrea Eisen, Shailendra Verma, Lavina Lickley, Dongsheng Tu, Karen Gelmon, Ralph Meyer, Will King. women: within chemoprevention trial. [abstract]. In: Proceedings Eleventh Annual AACR International Conference Frontiers Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Prev Res 2012;5(11 Suppl):Abstract nr B97.